By Fineline Cube Basecare Medical Device Co., Ltd. (HKG: 2170), a specialist in high-throughput sequencing-based assisted reproduction technologies, announced that China’s National Medical Products Administration (NMPA) has granted Category III medical device approval for its Gems oocyte retrieval solution family. The approval marks a significant milestone for the company’s expansion beyond genetic testing into core IVF consumables, with the solution serving as the first critical reagent in the in vitro fertilization (IVF) diagnostic and treatment process, providing essential conditions for successful fertilization, cleavage, and blastocyst development.
Regulatory Approval Details
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Company | Basecare Medical Device Co., Ltd. (HKG: 2170) |
| Product | Gems oocyte retrieval solution family |
| Classification | Category III medical device (highest risk classification) |
| Approval Date | 01 Jun 2026 |
| Market Significance | First core IVF reagent approval for Basecare beyond genetic testing |
| Target Application | In vitro fertilization (IVF) procedures |
Product Profile & Technical Specifications
- Primary Function: Oocyte retrieval solution – the foundational reagent in IVF procedures
- Antimicrobial Protection: Contains gentamicin sulfate to effectively mitigate sample contamination risks
- pH Stability: Equipped with HEPES buffering system maintaining stable pH levels in non-culture environments
- Versatility: Suitable for various oocyte retrieval scenarios and clinical protocols
- Shelf Life: 52 weeks of stable performance, significantly enhancing clinical convenience and inventory management
- Quality Assurance: Consistent performance across diverse laboratory conditions and operator skill levels
Strategic Market Implications
The NMPA approval positions Basecare to capture significant share in China’s rapidly expanding IVF consumables market, which is projected to reach ¥8–12 billion ($1.1–1.7 billion) annually by 2028:
- Market Integration: Leverages Basecare’s established relationships with 800+ reproductive medicine centers across China
- Vertical Expansion: Extends product portfolio from genetic testing services to essential IVF reagents
- Quality Differentiation: Category III approval validates product safety and efficacy for critical reproductive applications
- Clinical Workflow Enhancement: Comprehensive solution improves success rates and reduces procedural variability
“This Category III approval represents a strategic expansion of our assisted reproduction platform beyond genetic testing,” said Dr. Zhang Wei, Chief Executive Officer of Basecare Medical. “The Gems oocyte retrieval solution addresses a fundamental need in every IVF cycle, and its integration into our existing customer base creates immediate commercial opportunities while enhancing overall IVF success rates.”
Competitive Advantages & Commercial Outlook
Basecare’s entry into the IVF reagents market offers distinct advantages:
- Regulatory Leadership: Among the first domestic manufacturers to secure Category III approval for oocyte retrieval solutions
- Integrated Platform: Seamless compatibility with Basecare’s existing genetic testing and embryo screening services
- Quality Standards: Meets international quality benchmarks while offering competitive pricing versus imported alternatives
- Supply Chain Security: Domestic manufacturing ensures consistent availability and reduces import dependencies
The company expects immediate commercial launch across its established network of reproductive medicine centers, with potential for inclusion in provincial healthcare procurement programs given the product’s domestic origin and regulatory status.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial launches, and market opportunities for Basecare’s Gems oocyte retrieval solution. Actual results may differ due to market adoption patterns, competitive dynamics, and evolving regulatory requirements.-Fineline Info & Tech